Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 2197-2201, 2004. First published September 16, 2004; 10.1373/clinchem.2004.040154
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2004.040154v1
50/11/2197    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bornhorst, J. A.
Right arrow Articles by Roberts, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bornhorst, J. A.
Right arrow Articles by Roberts, W. L.
Related Collections
Right arrow Laboratory Management
Right arrow General Clinical Chemistry
(Clinical Chemistry. 2004;50:2197-2201.)
© 2004 American Association for Clinical Chemistry, Inc.

Technical Briefs

Assay-Specific Differences in Lipemic Interference in Native and Intralipid-Supplemented Samples

Joshua A. Bornhorst1, Richard F. Roberts2 and William L. Roberts1,a

1 Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT;2 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT;

aaddress correspondence to this author at: ARUP Laboratories, 500 Chipeta Way, Salt Lake City, UT 84108; fax 801-584-5207, e-mail William.Roberts@aruplab.com

The first 300 words of the full text of this article appear below.

Lipemia is a potential cause of analytical interference (1)(2). Determinations of the lipemic index (L-index) or triglyceride concentrations are used to quantify lipemia (3)(4). The soy-based lipid emulsion, Intralipid, has been used to simulate lipemia in interference studies (2)(5), but without evidence of how well it simulates naturally occurring lipemia.

Many serum proteins can be quantified by immunoturbidimetric assays (6). Lipemia interferes by altering light scattering (1). Manufacturers often provide guidelines for the maximum acceptable lipemia that have been established by interference experiments using Intralipid-supplemented samples. For the Modular Analytics P analyzer (Roche Diagnostics), the maximum allowable triglyceride values range from 4000 mg/L for the prealbumin assay to 20 000 mg/L for the haptoglobin assay. Sample turbidity is only weakly correlated with triglyceride concentration in patient samples (4). Thus, to test the validity of the lipemic thresholds, we directly compared interference from lipemic patient samples with interference induced by supplementation with Intralipid.

We prepared pooled samples by mixing excess serum from two to five individual patient samples. Samples were assayed immediately or were stored at 4 °C for up to 2 weeks before testing. Samples were mixed by multiple manual inversions before analysis. The 16 pooled samples were simultaneously assayed for L-index, triglycerides, {alpha}1-antitrypsin, ceruloplasmin, haptoglobin, prealbumin, and transferrin on a Modular Analytics P 800 analyzer. All results are the means of duplicate measurements.

The protein assays are non-particle-enhanced immunoturbidimetric assays. The primary assay wavelength is 700 nm and the secondary wavelength 340 nm, except for transferrin (secondary wavelength, 505 nm). All absorbances measured at these wavelengths were within the linear range of the photometer. Triglycerides were measured by a colorimetric enzymatic assay with a primary wavelength of 700 nm and a . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. H. Kroll
Evaluating Interference Caused by Lipemia
Clin. Chem., November 1, 2004; 50(11): 1968 - 1969.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.